These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8638357)

  • 1. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
    Narayan P; Trachtenberg J; Lepor H; Debruyne FM; Tewari A; Stone N; Das S; Jimenez-Cruz JF; Shearer R; Klimberg I; Schellhammer PF; Costello AJ
    Urology; 1996 Apr; 47(4):497-504. PubMed ID: 8638357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flutamide in treatment of benign prostatic hypertrophy.
    Stone NN
    Urology; 1989 Oct; 34(4 Suppl):64-8; discussion 87-96. PubMed ID: 2477936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    Lepor H; Machi G
    Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
    Moon KT; Yoo TK; Kwon SY; Ha JY; Byun SS; Kim JH; Chung JI; Kim TH; Moon HS; Kim SJ; Lee KS
    BJU Int; 2018 Aug; 122(2):283-292. PubMed ID: 29633507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The anti-androgen flutamide in the treatment of prostatic hyperplasia].
    Romics I; Bach D
    Orv Hetil; 1992 Nov; 133(47):3023-5. PubMed ID: 1279497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.
    Caine M; Perlberg S; Gordon R
    J Urol; 1975 Oct; 114(4):564-8. PubMed ID: 66331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
    J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China.
    Shi R; Xie Q; Gang X; Lun J; Cheng L; Pantuck A; Rao J
    J Urol; 2008 Feb; 179(2):610-5. PubMed ID: 18082217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.